Clinical trials: SCLC
NSCLC
Prophylactic Cranial Irradiation (PCI) Cognitive Tests in Non-small Cell Lung Cancer (NSCLC) Patients
Stage III non-small cell lung cancer (NSCLC) patients constitute a significant proportion of the lung cancer population. The prognosis of these patients has improved over the years due the introduction of combined modality…
- Trial name
- NCT01290809
- Where
- 4 sites in Netherlands
- Volunteers
- 170 people
- Sponsor
- Maastricht Radiation Oncology
Lung Cancer, NSCLC, Stage III
Sotorasib in Advanced KRASG12C-mutated Non-small Cell Lung Cancer Patients With Comorbidities
A single-arm, multicentre trial to investigate sotorasib in KRASG12C-mutated non-small cell lung cancer stage III/IV not amenable for curative treatment including patients with comorbidities, and to provide translational…
- Conditions
- Lung Cancer, NSCLC, Stage III, NSCLC Stage IV, Lung Cancer Stage IV
- Trial name
- SOLUCOM (NCT05311709)
- Testing
- sotorasib
- Where
- Norway
- Volunteers
- 100 people
- Sponsor
- Vestre Viken Hospital Trust
Carcinoma, Non-Small-Cell Lung, Lung Neoplasm
An Open Label Study of a Peptide Vaccine in Patients With Stage IIb or IIIa Non-Small Cell Lung Cancer
EP2101 is a new cancer vaccine containing 10 different peptide antigens. The vaccine is designed to activate the immune system to develop a response against tumor cells in order to delay or prevent the recurrence of cancer.
- Trial name
- NCT00054899
- Testing
- EP2101
- Where
- 8 sites in United States
- Volunteers
- 18 people
- Sponsor
- Epimmune
NSCLC
Multimodal Model Predicts Treatment Efficacy and CIP Risk in Advanced NSCLC With Immunotherapy and Chemotherapy
Immunotherapy is a crucial first-line treatment for advanced non-small cell lung cancer (NSCLC) without gene mutations. However, chemotherapy-induced pneumonitis (CIP) is a common adverse effect of immunotherapy, with severe…
- Trial name
- NCT07243899
- Testing
- This study is an observational study; the intervention is not applicable.
- Where
- China
- Volunteers
- 3,000 people
- Sponsor
- Shanghai Zhongshan Hospital
Cancer
Whole Brain Radiation With or Without Erlotinib for Brain Metastases From Non-Small Cell Lung Cancer
To determine if erlotinib given orally along with concurrent whole brain irradiation in lung cancer patients with brain metastases improves median overall survival and enhances local control compared to those treated with WBRT…
- Trial name
- RadEr (NCT01518621)
- Testing
- Radiation, Radiation plus erlotinib
- Where
- Norway
- Volunteers
- 25 people
- Sponsor
- Oslo University Hospital
Stage IIIA Non-small Cell Lung Cancer, Stage IIIB Non-small Cell Lung Cancer
Vorinostat, Paclitaxel, and Radiation Therapy in Treating Patients Unable to Tolerate Cisplatin With Stage III Non-Small Lung Cancer That Cannot Be Removed By Surgery
This phase I/II trial studies the side effects and best dose of vorinostat when given together with paclitaxel and radiation therapy and to see how well it works in treating patients unable to tolerate cisplatin with stage III…
- Trial name
- NCT00662311
- Testing
- vorinostat, paclitaxel, radiation therapy
- Where
- United States
- Volunteers
- 5 people
- Sponsor
- University of Washington
Lung Cancer
MDT-bridged Radical Therapy After Aumolertinib With MRD-guided Maintenance in EGFRm+ Unresectable Stage III NSCLC (APPROACH)
This is an open-label, multi-center, randomized, phase III study. It is aimed to firstly evaluate the effectiveness and safety of almonertinib induction therapy in EGFR-mutated patients with unresectable stage III non-small cell…
- Trial name
- APPROACH (NCT04841811)
- Testing
- Almonertinib
- Where
- China
- Volunteers
- 192 people
- Sponsor
- Guangdong Association of Clinical Trials
Advanced Non-small Cell Lung Cancer
Observational Cohort Study of Advanced Non-small Cell Lung Cancer (CAPTRA-LUNG)
Investigators propose to establish and maintain a cohort of patients with advanced non-small cell lung cancer, and to assess the treatment pattern, host genetic, and clinical factors which influence the prognosis and survival, as…
- Trial name
- NCT03334864
- Where
- China
- Volunteers
- 5,000 people
- Sponsor
- Peking Union Medical College Hospital
Non-small-cell Lung Cancer
A Study of AUY922 in Non-small-cell Lung Cancer Patients Who Have Received Previous Two Lines of Chemotherapy.
This study will assess the efficacy of AUY922, when administered weekly at 70 mg/m2, in adult patients with advanced Non-small-cell Lung Cancer (NSCLC), who have received at least two prior lines of chemotherapy.
- Trial name
- NCT01124864
- Testing
- AUY922
- Where
- 22 sites in United States, Canada and 8 more
- Volunteers
- 153 people
- Sponsor
- Novartis Pharmaceuticals
Lung Cancer
Genetic Changes in Patients With Non-Small Cell Lung Cancer Who Are Receiving Vinorelbine and Gemcitabine Before Surgery
RATIONALE: Determination of genetic changes in patients with non-small cell lung cancer may help predict the outcome of treatment.
- Trial name
- NCT00057798
- Testing
- gemcitabine hydrochloride, vinorelbine ditartrate, cytogenetic analysis
- Where
- United States
- Volunteers
- 21 people
- Sponsor
- Roswell Park Cancer Institute
Lung Cancer, Esophageal Cancer
Pulsed Low Dose Rate Radiation With Concurrent Chemotherapy for Non-Small Cell Lung Cancer and Esophageal Cancer
Phase I study with the hypothesis that Pulsed Low Dose Radiation (PLDR) radiation delivery technique can significantly decrease the rate of severe acute esophagitis in patients receiving concurrent Chemo-radiation therapy (CRT)…
- Trial name
- NCT03094884
- Testing
- Pulsed Low Dose Radiation, Carboplatin, Paclitaxel
- Where
- United States
- Volunteers
- 40 people
- Sponsor
- Fox Chase Cancer Center
Non-small Cell Lung Cancer
T-Cell PET Imaging With [18F]F-AraG in Lung Cancer
This is a single-center cross-sectional imaging study in patients with localized lung cancer undergoing immunotherapy with or without stereotactic radiation therapy as part of the companion clinical trial (NCT03217071…
- Trial name
- NCT03311672
- Testing
- [18F]F-Ara-G, Pembrolizumab, PET/CT scan
- Sponsor
- University of California, San Francisco
Non-small Cell Lung Cancer, Lung Cancer
ALTA-1L Study: A Study of Brigatinib Versus Crizotinib in Anaplastic Lymphoma Kinase Positive (ALK+) Advanced Non-small Cell Lung Cancer (NSCLC) Participants
The purpose of the study is to compare the efficacy of brigatinib to that of crizotinib in ALK+ locally advanced or metastatic non-small cell lung cancer (NSCLC) participants naive to ALK inhibitors, as evidenced by…
- Conditions
- Non-small Cell Lung Cancer, Lung Cancer, Advanced Malignancies, Carcinoma
- Trial name
- ALTA-1L (NCT02737501)
- Testing
- Brigatinib, Crizotinib
- Where
- 91 sites in United States, Australia and 17 more
- Volunteers
- 275 people
- Sponsor
- Ariad Pharmaceuticals
Non-Small Cell Lung Cancer
SFRT+Tislelizumab+Platinum Chemotherapy for Unresectable Stage III NSCLC
The aim of this clinical trial is to understand whether spatial fractionated radiotherapy (SFRT) in combination with tislelizumab and platinum-based doublet chemotherapy given concurrently as induction treatment is effective in…
- Trial name
- NCT07131319
- Testing
- Spatially Fractionated Radiotherapy (SFRT), Tislelizumab, Carboplatin, Pemetrexed, Tislelizumab, paclitaxel, Carboplatin
- Where
- China
- Volunteers
- 30 people
- Sponsor
- Second Affiliated Hospital of Nanchang University
Non Small Cell Lung Cancer, Colorectal Cancer
A Study of YL202 in Patients With Advanced Solid Tumors
This study is a multicenter, open-label, phase II study of YL202 in China to evaluate the efficacy, safety, and PK characteristics of YL202 in selected patients with advanced solid tumors.
- Conditions
- Non Small Cell Lung Cancer, Colorectal Cancer, Cervical Cancer, Locally Advanced or Metastatic Solid Tumors
- Trial name
- NCT07202364
- Testing
- YL202
- Where
- China
- Volunteers
- 100 people
- Sponsor
- MediLink Therapeutics (Suzhou) Co., Ltd.
Non Small Cell Lung Cancer
Docetaxel/Pemetrexed as 1st Line Treatment in Patients With Non Small Cell Lung Cancer (NSCLC)
This trial will determine the maximum tolerated dose the recommended phase II dose and the efficacy of this combination in locally advanced or metastatic NSCLC patients
- Trial name
- NCT00684099
- Testing
- Docetaxel, Pemetrexed
- Where
- 8 sites in Greece
- Volunteers
- 70 people
- Sponsor
- Hellenic Oncology Research Group
Small Cell Lung Cancer
TS Overexpression in SCLC: Mechanism and Therapeutic Targeting
The purpose of this research study is to determine the amount of a protein named thymidine synthase that is being made by cancer and to develop laboratory models called PDX (patient derived xenografts) to learn more about SCLC…
- Trial name
- NCT03741829
- Where
- United States
- Volunteers
- 12 people
- Sponsor
- Wake Forest University Health Sciences
Bladder Cancer, Breast Cancer
Irinotecan Plus Gemcitabine in Treating Patients With Unresectable or Metastatic Solid Tumors
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug may kill more tumor cells.
- Conditions
- Bladder Cancer, Breast Cancer, Colorectal Cancer, Kidney Cancer
- Trial name
- NCT00004095
- Testing
- gemcitabine hydrochloride, irinotecan hydrochloride
- Where
- United States
- Volunteers
- 38 people
- Sponsor
- Northwestern University
Non-Small Cell Lung Cancer(NSCLC)
Neoadjuvant WX-0593 in Resectable ALK-positive or ROS1-positive Non-small Cell Lung Cancer
This is a single-arm, exploratory trial to evaluate the efficacy and safety of neoadjuvant WX-0593 in patients with resectable ALK-positive or ROS1- positive non-small cell lung cancer(NSCLC).
- Trial name
- NCT05765877
- Testing
- WX-0593 Tablets
- Where
- China
- Volunteers
- 26 people
- Sponsor
- Pingping Song
Non-small Cell Lung Cancer (NSCLC), Cachexia
A Study to Learn About the Study Medicine Called Ponsegromab in Adults With Lung Cancer-Associated Significant Body Weight Loss
Study to investigate the effect of ponsegromab on skeletal muscle mass and physical function in adult participants with non-small cell lung cancer associated cachexia.
- Trial name
- NCT07663630
- Testing
- ponsegromab
- Where
- 7 sites in United States, China
- Volunteers
- 80 people
- Sponsor
- Pfizer